Recombinant anti-tumor RNAse

Details Recombinant anti-tumor RNAse Recombinant anti-tumor RNAse

2005-03-22

2005-03-22

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

C435S183000, C435S199000

Reexamination Certificate

active

06869604

ABSTRACT:
This invention provides for new recombinant ribonuclease proteins which are active when expressed by bacteria. This allows the recombinant ribonucleases of this invention to be fused in-frame with ligand binding moieties to form cytotoxic fusion proteins. Furthermore, these proteins are more active than ribonucleases currently available even though the proteins of this invention lack an N-terminal pyroglutamic acid, which has been found to be necessary for ribonucleolytic activity. Because these proteins are recombinant proteins, mutations which increase cytotoxicity can be engineered.

REFERENCES:
patent: 5728805 (1998-03-01), Ardelt
patent: 5840840 (1998-11-01), Rybak et al.
patent: 6395276 (2002-05-01), Rybak et al.
patent: WO9731116 (1997-08-01), None
patent: WO9738112 (1997-10-01), None
patent: WO9850435 (1998-11-01), None
patent: WO9950398 (1999-10-01), None
Voet et al (1990, Biochemistry, John Wilis & Sons, p. 61 only).*
Joshi et al (J Pharm Sci. Nov. 2002; 91(11): 2331-45).*
Newton et al (1998, Biochemistry vol. 37, pp. 5173-5183).*
Newton et al (1997, Protein Engineering, vol. 10, pp. 463-470.*
Chen et al, Nucleic Acids Res. Jun. 15, 2000; 28(12): 2375-82.*
Ardelt et al (J. Biol. Chem. vol. 266, pp. 245-251).*
Bowie et al (Science, 1990, 247:1306-1310).*
Burgess et al (J of Cell Bio. 111:2129-2138, 1990).*
Lazar et al (Molecular and Cellular Biology, 1988, 8:1247-1252).*
Rybak et al (1991, J. Biol. Chem. vol. 266, pp. 21202-21207, abstract only).*
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).*
Dermer (Bio/Technology, 1994, 12:320).*
Gura (Science, 1997, 278:1040-1042).*
Jain (Sci. Am., 1994, 271:58-65).*
Curti (Crit. Rev. in Oncology/Hematology, 1993, 14:29-39).*
Hartwell et al (Science, 1997, 278:1064-1068).*
Berg et al (Mar. 5, 1999, Cancer Research 59, 1180-1183).*
Bowie et al (Science, 1990, 247:1306-1310).*
Wang, J. et al. 2000 J. Biol. Chem. 275 (1): 507-513.*
Ardelt, et al. “Amino Acid Sequence of an Anti-tumor Protein from Rana Pipiens Oocytes and Early Embryosis/Homology to Pancreatic Ribonuclease”J. of Biological Chemistry, (Jan. 1991), vol. 266(1), pp. 245-251.
Boix, et al. “Role of the N terminus in Rnase A Homologues: Differences in Catalytic Activity, Ribonuclease Inhibitor Interaction and Cytotoxicity”J. of Molecular Biology(Jan. 1996), vol. 266(1), pp. 257, pp. 992-1007.
Inokuchi, et al. “Primary Structure of Base Non-specific and Acid Ribonuclease from Bullfrog (Rana catesbeiana)”Biol. Pharm. Bull(1997) vol. 20(5).
Kobe, et al. “A Structural Basis of the Interactions Between Leucine-rich Repeats and Protein Ligands”Nature, (Mar. 1995), vol. 374, pp. 183-186.
Leung, et al. “Recombinant Expression of Ribonuclease ofRana pipienOrigin” Mar. 1999 vol. 40, pp. 353-354.
Liao, et al. “Large-Scale Preparation of a Ribonuclease fronRana catesbeiana(Bullfrog) Oocytes and Characterization of its Specific Cytotoxic Activity Against Tumor Cells”Protein Expression and Purification(1996) vol. 7, pp. 194-202.
Mansfield, et al. “Recombinant RFB4 Immunotoxins Exhibit Potent Cytotoxic Activity for CD22-bearing Cells and Tumors”Blood(Sep. 1997) vol. 90(5), pp. 2020-2026.
Mansfield, et al. “Recombinant RFB4 Single-chain Immunotoxin that is Cytotoxic Towards CD22-positive Cells”Biochem. Soc. Trans.(1997) vol. 25, pp. 709-714.
Mosimann, et al. “Refined 1.7 AA X-ray Crystallographic Structure P-30 Protein, Amphibian Ribonuclease with Anti-tumor Activity”J. of Molecular Biology, Jan. 1994, vol. 236 (4), pp. 1141-1153.
Newton, et al. “Anti-tumor Ribonuclease, combined with or Conjugated to Monclonal Antibody MRK16, Overcomes Multidrug Resistance to Vincristine In Vitro and In Vivo”Int'l. Oncology(1996) vol. 8, pp. 1095-1104.
Newton, et al. “Angiogenin Single-chain Immunofusions: Influence of Peptide Linkers and Spacers Between Fusion Protein Domains”Biochemistry(1996) vol. 35, pp. 545-553.
Newton, et al. “Expression and Characterization of a Cytotoxic Human-frog Chimeric Ribonuclease: Potential for Cancer Therapy”Protein Engineering(1997) vol. 10(4), pp. 463-470.
Newton, et al. “Single Amino-acid Substitutions at the N-terminus of a Recombinant Cytotoxic Ribonuclease Markedly Influence Biochemical and Biological Properties”Biochemistry, Apr. 1998, vol. 37 (15), pp. 5173-5183.
Ryback, et al. “Cytoxic Onconase and Ribonuclease a Chimeras: Comparison and in Vitro Characterization”Drug Delivery(1993) vol. 1, pp. 3-10.

Affiliated with

Also associated with

Rating

Recombinant anti-tumor RNAse does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Recombinant anti-tumor RNAse, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Recombinant anti-tumor RNAse will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3456816